3 Biotechs Awaiting FDA Approval Decisions

In the days before electronic filing, new drug applications required so much paper they could fill entire offices from floor to ceiling. Just getting the U.S. Food and Drug Administration (FDA) to officially begin reviewing one is an accomplishment.

All three of these biotech stocks could move in the weeks ahead, because the FDA is expected to hand down decisions regarding some applications currently under review. Here's what you need to know.